Bio Rad Laboratories Inc rises amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Jan 26
Source: 144
Bio Rad Laboratories Inc experienced a price increase of 5.08%, crossing above its 5-day SMA. This movement aligns with the broader market context, as the Nasdaq-100 rose by 0.84% and the S&P 500 gained 0.73%.
The stock's rise is attributed to broad market strength, which has positively influenced investor sentiment across various sectors. The overall market trend has provided a favorable environment for stocks like Bio Rad Laboratories Inc to gain traction.
As the market continues to show strength, Bio Rad Laboratories Inc's performance may reflect ongoing investor confidence, potentially leading to further upward momentum in the near term.
Analyst Views on BIO
Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 357.50 USD with a low forecast of 340.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 299.790
Low
340.00
Averages
357.50
High
375.00
Current: 299.790
Low
340.00
Averages
357.50
High
375.00
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
